AstraZeneca PLC Form 6-K Filing Summary

This report details the positive results of the SANOVO Phase III trial for AstraZeneca PLC, evaluating Tagrisso in combination with Orpathys for first-line treatment of EGFR-mutated lung cancer with MET overexpression. The combination demonstrated a statistically significant improvement in progression-free survival (PFS) and encouraging overall survival (OS) compared to Tagrisso alone. These findings, consistent with previous trials, reinforce Tagrisso's role as a backbone therapy and suggest a potential shift in treatment strategy for this patient population. The safety profile was consistent with known data, and further presentation and regulatory discussions are planned. The report also provides background on lung cancer, MET aberrations, and details on the SANOVO trial, Orpathys, and Tagrisso medications, highlighting AstraZeneca's ongoing commitment to advancing lung cancer treatment.